Aclaris Therapeutics (ACRS) Reports In-Line Q4 EPS, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments
March 18, 2019 7:01 AM EDTProduct Sales of $3.9 Million for Fiscal Year 2018Initiates Financial Guidance for Full Year 2019Management to Host Conference Call at 8:00 AM ET today
WAYNE, Pa., March 18, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced financial results for the fourth quarter and full year 2018, and provided an update on its clinical development and commercial programs.  Â
In November 2018, Aclaris acquired the worldwide rights to RHOFADE® (oxymetazoline hydrochloride) cream, 1% from... More